dc.creator | Cabeza Montilla, Laura | es |
dc.creator | El-Hammadi, Mazen | es |
dc.creator | Ortíz Quesada, Raúl | es |
dc.creator | Cayero Otero, María Dolores | es |
dc.creator | Jiménez López, Julia | es |
dc.creator | Perazzoli, Gloria | es |
dc.creator | Martín Banderas, Lucía | es |
dc.creator | Baeyens Cabrera, José Manuel | es |
dc.creator | Melguizo Alonso, Consolación | es |
dc.creator | Prados, José | es |
dc.date.accessioned | 2022-11-02T15:03:19Z | |
dc.date.available | 2022-11-02T15:03:19Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Cabeza Montilla, L., El-Hammadi, M., Ortíz Quesada, R., Cayero Otero, M.D., Jiménez López, J., Perazzoli, G.,...,Prados, J. (2022). Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer. BioImpacts, 12. https://doi.org/10.34172/bi.2022.23433. | |
dc.identifier.issn | 2228-5652 | es |
dc.identifier.issn | 2228-5660 | es |
dc.identifier.uri | https://hdl.handle.net/11441/138602 | |
dc.description.abstract | Introduction: Paclitaxel (PTX) is a cornerstone in the treatment of breast cancer, the most common type of cancer in women. However, this drug has serious limitations, including lack of tissue-specificity, poor water solubility, and the development of drug resistance. The transport of PTX in a polymeric nanoformulation could overcome these limitations.
Methods: In this study, PLGA-PTX nanoparticles (NPs) were assayed in breast cancer cell lines, breast cancer stem cells (CSCs) and multicellular tumor spheroids (MTSs) analyzing cell cycle, cell uptake (Nile Red-NR-) and α-tubulin expression. In addition, PLGA-PTX NPs were tested in vivo using C57BL/6 mice, including a biodistribution assay.
Results: PTX-PLGA NPs induced a significant decrease in the PTX IC50 of cancer cell lines (1.31 and 3.03-fold reduction in MDA-MB-231 and E0771 cells, respectively) and CSCs. In addition, MTSs treated with PTX-PLGA exhibited a more disorganized surface and significantly higher cell death rates compared to free PTX (27.9% and 16.3% less in MTSs from MCF-7 and E0771, respectively). PTX-PLGA nanoformulation preserved PTX’s mechanism of action and increased its cell internalization. Interestingly, PTX-PLGA NPs not only reduced the tumor volume of treated mice but also increased the antineoplastic drug accumulation in their lungs, liver, and spleen. In addition, mice treated with PTX-loaded NPs showed blood parameters similar to the control mice, in contrast with free PTX.
Conclusion: These results suggest that our PTX-PLGA NPs could be a suitable strategy for breast cancer therapy, improving antitumor drug efficiency and reducing systemic toxicity without altering its mechanism of action. | es |
dc.description.sponsorship | Junta de Andalucía PI-0102-2017, P18-HO-3882 | es |
dc.description.sponsorship | Instituto de Salud Carlos III PI19/01478 | es |
dc.format | application/pdf | es |
dc.format.extent | 17 p. | es |
dc.language.iso | eng | es |
dc.publisher | Universidad de Ciencias Médicas de Tabriz | es |
dc.relation.ispartof | BioImpacts, 12. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Paclitaxel | es |
dc.subject | PLGA | es |
dc.subject | Breast cancer | es |
dc.subject | Cancer stem cells | es |
dc.subject | Mice xenografts | es |
dc.title | Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéutica | es |
dc.relation.projectID | PI-0102-2017 | es |
dc.relation.projectID | P18-HO-3882 | es |
dc.relation.projectID | PI19/01478 | es |
dc.relation.publisherversion | http://doi.org/10.34172/bi.2022.23433 | es |
dc.identifier.doi | 10.34172/bi.2022.23433 | es |
dc.journaltitle | BioImpacts | es |
dc.publication.volumen | 12 | es |
dc.contributor.funder | Universidad de Sevilla | es |
dc.contributor.funder | Junta de Andalucía | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |